Bladder Cancer

A study presented at the American Society of Hematology’s Meeting and Exposition found that cells genetically edited using CRISPR/Cas9 technology and infused back into patients with multiple myeloma and sarcoma appeared safe and feasible. This was among the week’s top stories in hematology/oncology.

The FDA granted priority review to a supplmemental biologics license application that seeks approval of pembrolizumab for treatment of certain patients with high-risk, nonmuscle-invasive bladder cancer.

There is an association between certain types of commensal urinary microbiome bacteria found in the urinary tract and a clinical response to bacillus Calmette-Guérin immunotherapy for patients with early-stage urothelial bladder cancer, according to results of an investigator-initiated, single institution pilot study presented at Society for Immunotherapy of Cancer Annual Meeting.

Investigators from Georgetown University Medical Center and Fudan University in China have developed a novel noninvasive and individualized technique for the detection and treatment of bladder cancer.

A novel therapeutic treatment using a common cold virus could be effective in patients with nonmuscle-invasive bladder cancer, and breast cancer history was associated with an increased risk for congestive heart failure later in life.

A novel therapeutic approach that involves the oncolytic virus coxsackievirus showed potential among a small cohort of patients with nonmuscle-invasive bladder cancer, according to study findings published in Clinical Cancer Research.

Bacillus Calmette-Guérin, or BCG, is highly effective at treating and preventing recurrence of early-stage bladder cancer.

The addition of atezolizumab to platinum-based chemotherapy extended PFS among patients with previously untreated advanced bladder cancer, according to results released by the agent’s manufacturer.

Erdafitinib induced a high rate of objective tumor response in patients with locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations, according to results of a single-arm phase 2 study published in The New England Journal of Medicine.

This episode discusses the case of an 85-year-old man with a history of hypertension and fairly recently diagnosed bladder cancer who presents with oligoarticular asymmetric inflammatory arthritis. Explore the details of this case and learn how bacillus Calmette-Guérin and reactive arthritis are related in this diagnostic conundrum.